Today, Friends of Cancer Research (Friends) announced the launch of Phase II of its tumor mutational burden or TMB Harmonization Project as the TMB harmonization team finalizes data collected from the Phase I in silico analysis.
"Recent data shows a role for TMB in identifying patients more likely to respond to immunotherapy," said Friends' President & CEO, Jeff Allen. "However, harmonizing the measurement of TMB will be an important step in helping to reduce variability and optimize its use in cancer research and care. As we begin Phase II, I look forward to working with our partners and the team maneuvering through the data to come to consensus solutions. This has been a truly collaborative effort.”